2024
Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab
Galderisi A, Sims E, Evans-Molina C, Petrelli A, Cuthbertson D, Nathan B, Ismail H, Herold K, Moran A. Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab. Diabetologia 2024, 68: 646-661. PMID: 39560746, PMCID: PMC11832608, DOI: 10.1007/s00125-024-06323-0.Peer-Reviewed Original ResearchProgrammed death-1AUC C-peptideSlow progressorsRapid progressorsInsulin secretionInsulin clearanceC-peptideDisease-free survival ratesT effector memory cellsCD8+ T effector memory cellsNatural historyImpact of immunotherapyPlacebo-treated individualsT memory cellsBaseline insulin secretionBeta cell functionInterpreting clinical trialsLoss of insulin secretionDeath-1Elevated insulin secretionPlacebo-treatedTreatment armsTeplizumabClinical trialsDisposition indexTotal neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center.
Wang M, Gwee Y, Lin Z, Yong W, Sundar R, Tan H, Choo J, Tan K, Lieske B, Cheong W, Tan T, Tey J, Chee C, Chan G. Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center. Journal Of Clinical Oncology 2024, 42: 39-39. DOI: 10.1200/jco.2024.42.3_suppl.39.Peer-Reviewed Original ResearchLocally Advanced Rectal CancerTotal neoadjuvant therapyPathological complete responseDisease-free survivalClinical complete responseCircumferential resection marginCycles of XELOXTumor regression gradeCycles of mFOLFOX6Systemic chemotherapyComplete responseR0 resectionRectal cancerRate of clinical complete responseCycles of systemic chemotherapyPathologic complete response rateThreatened circumferential resection marginCircumferential resection margin involvementDisease-free survival ratesWatch-and-wait approachLimitations of retrospective studiesLong-course CRTMedian tumor distanceAdequate organ functionLong-course chemoradiation
2019
Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung Cancer
Haro GJ, Sheu B, Cook NR, Woodard GA, Mann MJ, Kratz JR. Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung Cancer. JAMA Network Open 2019, 2: e1917062. PMID: 31808928, PMCID: PMC6902768, DOI: 10.1001/jamanetworkopen.2019.17062.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerTNM staging systemDisease-free survivalHigh-risk patientsCell lung cancerStaging systemEighth editionSurgical resectionLung cancerConventional TNMPrognostic classifierNonsquamous non-small cell lung cancerQuaternary care medical centerDisease-free survival ratesHigh molecular riskSurvival 3 yearsEarly-stage diseaseConventional TNM stagingCritical unmet needCohort studyPrimary outcomeConsecutive seriesTNM stagingMolecular riskConcordance index
2018
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England Journal Of Medicine 2018, 379: 122-137. PMID: 29863451, PMCID: PMC6193457, DOI: 10.1056/nejmoa1803164.Peer-Reviewed Original ResearchConceptsTamoxifen plus ovarian suppressionTamoxifen-alone groupOvarian suppressionPremenopausal womenBreast cancerAdverse eventsOverall survivalDisease-free survival ratesOvarian Function TrialYears of tamoxifenAdjuvant endocrine therapyHigher adverse eventsReceipt of chemotherapyPremenopausal breast cancerLow recurrence rateAromatase inhibitor exemestaneUse of exemestaneSuppression groupExemestane TrialDistant recurrenceEndocrine therapyRecurrence rateGrade 3ExemestaneTamoxifenADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection
Wu YL, Herbst R, Mann H, Rukazenkov Y, Marotti M, Tsuboi M. ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection. Clinical Lung Cancer 2018, 19: e533-e536. PMID: 29789220, DOI: 10.1016/j.cllc.2018.04.004.Peer-Reviewed Original ResearchConceptsCell lung cancerDisease recurrenceLung cancerMutation statusSurvival rateEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsComplete surgical tumor resectionDisease-free survival ratesT790M mutation statusReceptor tyrosine kinase inhibitorsMaximum treatment durationStage IB-IIIAPlacebo-controlled studyDisease-free survivalEarly-stage NSCLCComplete surgical resectionOverall survival rateHealth-related qualityHealth resource useSurgical tumor resectionEGFR mutation statusTyrosine kinase inhibitorsCentral confirmationVersus Placebo
2016
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. New England Journal Of Medicine 2016, 375: 209-219. PMID: 27264120, PMCID: PMC5024713, DOI: 10.1056/nejmoa1604700.Peer-Reviewed Original ResearchConceptsContralateral breast cancerDisease-free survivalAromatase inhibitorsBreast cancerOverall survivalDisease-free survival ratesPositive early breast cancerAdjuvant aromatase inhibitorsNew-onset osteoporosisPlacebo-controlled trialPrimary end pointEarly breast cancerAnnual incidence rateTreatment of choiceBreast cancer recurrenceExtension of treatmentQuality of lifeBone painLetrozole groupAdjuvant therapyPlacebo groupPostmenopausal womenDisease recurrenceIncidence rateLower incidence
2015
Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research
Burke M, Verneris M, Le Rademacher J, He W, Abdel-Azim H, Abraham A, Auletta J, Ayas M, Brown V, Cairo M, Chan K, Diaz Perez M, Dvorak C, Egeler R, Eldjerou L, Frangoul H, Guilcher G, Hayashi R, Ibrahim A, Kasow K, Leung W, Olsson R, Pulsipher M, Shah N, Shah N, Thiel E, Talano J, Kitko C. Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. Transplantation And Cellular Therapy 2015, 21: 2154-2159. PMID: 26327632, PMCID: PMC4654112, DOI: 10.1016/j.bbmt.2015.08.023.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAcute DiseaseAdolescentBone Marrow TransplantationChildChild, PreschoolChronic DiseaseFemaleGraft vs Host DiseaseHumansImmunosuppressive AgentsInternational CooperationMaleMyeloablative AgonistsPrecursor T-Cell Lymphoblastic Leukemia-LymphomaProspective StudiesRecurrenceRemission InductionSeverity of Illness IndexSurvival AnalysisTransplantation ConditioningTransplantation, HomologousTreatment OutcomeConceptsHematopoietic cell transplantationT-cell acute lymphoblastic leukemiaCell acute lymphoblastic leukemiaMarrow Transplant ResearchAcute lymphoblastic leukemiaInternational BloodLymphoblastic leukemiaTransplant ResearchRelapsed T-cell acute lymphoblastic leukemiaThree-year overall survivalAllogeneic hematopoietic cell transplantationDisease-free survival ratesBone marrow/peripheral bloodTransplant-related mortalitySecond complete remissionBone marrow relapseUmbilical cord bloodPediatric T-ALLChronic graftExtramedullary relapseSecond remissionComplete remissionExtramedullary diseaseHost diseaseMarrow relapse
2014
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD. Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. New England Journal Of Medicine 2014, 372: 436-446. PMID: 25495490, PMCID: PMC4341825, DOI: 10.1056/nejmoa1412379.Peer-Reviewed Original ResearchConceptsTamoxifen plus ovarian suppressionOvarian suppressionRate of freedomBreast cancerTamoxifen groupPremenopausal womenPrimary analysisDisease-free survival ratesPositive early breast cancerAdjuvant ovarian suppressionNonreceipt of chemotherapyYears of tamoxifenDisease-free survivalPremenopausal breast cancerEarly breast cancerOvarian estrogen productionOverall study populationSuppression groupGreater treatment effectUse of exemestaneAdjuvant chemotherapyPrior chemotherapyMost recurrencesPrognostic factorsPrior receiptAfatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial
Burtness B, Bourhis JP, Vermorken JB, Harrington KJ, Cohen E. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. Trials 2014, 15: 469. PMID: 25432788, PMCID: PMC4289298, DOI: 10.1186/1745-6215-15-469.Peer-Reviewed Original ResearchMeSH KeywordsAfatinibAntineoplastic AgentsCarcinoma, Squamous CellChemoradiotherapyChemotherapy, AdjuvantClinical ProtocolsDisease-Free SurvivalDouble-Blind MethodErbB ReceptorsHead and Neck NeoplasmsHumansMolecular Targeted TherapyNeoplasm Recurrence, LocalNeoplasm StagingProtein Kinase InhibitorsQuality of LifeQuinazolinesResearch DesignRisk FactorsSquamous Cell Carcinoma of Head and NeckTime FactorsTreatment OutcomeConceptsEpidermal growth factor receptorDisease-free survivalErbB family membersAdvanced diseaseOropharynx cancerOverall survivalEndpoint measuresUnfavourable riskPrimary siteHigh-risk HNSCC patientsHPV-positive oropharynx cancerIrreversible ErbB family blockerDisease-free survival ratesRandomized phase II trialNeck squamous cell carcinomaErbB family blockerHigh-risk headHigh-risk HNSCCPrimary endpoint measureGood clinical conditionEvidence of diseaseLymph node involvementPhase II trialPhase III studyUnacceptable adverse events
2010
Use of a Conventional Low Neck Field (LNF) and Intensity-Modulated Radiotherapy (IMRT): No Clinical Detriment of IMRT to an Anterior LNF During the Treatment of Head-and Neck-Cancer
Turaka A, Li T, Nicolaou N, Lango MN, Burtness B, Horwitz EM, Ridge JA, Feigenberg SJ. Use of a Conventional Low Neck Field (LNF) and Intensity-Modulated Radiotherapy (IMRT): No Clinical Detriment of IMRT to an Anterior LNF During the Treatment of Head-and Neck-Cancer. International Journal Of Radiation Oncology • Biology • Physics 2010, 79: 65-70. PMID: 20385457, PMCID: PMC3339153, DOI: 10.1016/j.ijrobp.2009.10.034.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Squamous CellChi-Square DistributionCombined Modality TherapyDisease-Free SurvivalFemaleFollow-Up StudiesGastrostomyHead and Neck NeoplasmsHumansLinear ModelsLymph Node ExcisionMaleMiddle AgedRadiotherapy DosageRadiotherapy, Intensity-ModulatedRetrospective StudiesTreatment FailureConceptsIntensity-modulated radiotherapyLow-neck fieldLower neckDisease-free survival ratesPercutaneous endoscopic gastrostomy tubeNeck fieldSingle-institution studySquamous cell carcinomaLog-rank testTreatment of headAnterior photon fieldAnterior low-neck fieldClinical detrimentCurative intentMedian ageClinical outcomesGastrostomy tubeNeck diseasePEG tubeCell carcinomaNeck cancerPhysician preferenceRegional failureStage IIIPatients
2009
Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival
Palavecino M, Chun YS, Madoff DC, Zorzi D, Kishi Y, Kaseb AO, Curley SA, Abdalla EK, Vauthey JN. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery 2009, 145: 399-405. PMID: 19303988, DOI: 10.1016/j.surg.2008.10.009.Peer-Reviewed Original ResearchConceptsPreoperative portal vein embolizationMajor hepatic resectionPreoperative PVEPVE groupHepatic resectionPortal vein embolizationHepatocellular carcinomaPerioperative outcomesDFS ratesPerioperative deathsVein embolizationSurvival rateDisease-free survival ratesPreoperative transarterial chemoembolizationOverall postoperative complicationsRemnant liver volumeImproved perioperative outcomesOverall survival rateAmerican Joint CommitteeHepatitis B virusHepatitis C virusPerioperative mortalityPerioperative riskPostoperative complicationsOverall survival
2008
Current Role of Surgery in Treatment of Early Stage Hepatocellular Carcinoma: Resection versus Liver Transplantation
Yi N, Suh K, Kim T, Kim J, Shin W, Lee K. Current Role of Surgery in Treatment of Early Stage Hepatocellular Carcinoma: Resection versus Liver Transplantation. Oncology 2008, 75: 124-128. PMID: 19092282, DOI: 10.1159/000173434.Peer-Reviewed Original ResearchConceptsStage hepatocellular carcinomaHepatocellular carcinomaLiver transplantationMilan criteriaDisease-free survival ratesEarly stage hepatocellular carcinomaEarly stage HCCAssociated with hepatitis B infectionLT to patientsChild A cirrhosisCurative treatment optionDecompensated liver cirrhosisHepatitis B infectionSelection criteria of LTEarly stage patientsCurative intentLiver resectionB infectionStage patientsLifelong immunosuppressionPrimary treatmentTreatment optionsLiver cirrhosisCirrhotic liverSurvival rateGemtuzumab Ozogamicin (GO) and Continuous Infusion Cytarabine (ARA-C) for Relapsed/Refractory Acute Myeloid Leukemia (AML) Prior to Allogeneic Stem Cell Transplantation (SCT).
Zeidan A, Tan W, Wilding G, Ford L, Hahn T, Smiley S, Battiwalla M, McCarthy P, Wang E, Wetzler M. Gemtuzumab Ozogamicin (GO) and Continuous Infusion Cytarabine (ARA-C) for Relapsed/Refractory Acute Myeloid Leukemia (AML) Prior to Allogeneic Stem Cell Transplantation (SCT). Blood 2008, 112: 952. DOI: 10.1182/blood.v112.11.952.952.Peer-Reviewed Original ResearchDonor stem cell transplantationRefractory acute myeloid leukemiaAllogeneic stem cell transplantationStem cell transplantationAcute myeloid leukemiaUnrelated donor stem cell transplantationGemtuzumab ozogamicinBone marrow aspirationMarrow aplasiaEvaluable ptsInfectious complicationsMarrow aspirationRelapsed/Refractory Acute Myeloid LeukemiaRelated donor stem cell transplantationAcute GVHD grade IILower-intensity conditioning regimensDisease-free survival ratesContinuous infusion araContinuous infusion cytarabineGVHD grade IIIntensity conditioning regimensComplete remission durationDays post inductionAML ptsChronic GVHD
2007
Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival
Chun YS, Vauthey JN, Ribero D, Donadon M, Mullen JT, Eng C, Madoff DC, Chang DZ, Ho L, Kopetz S, Wei SH, Curley SA, Abdalla EK. Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival. Journal Of Gastrointestinal Surgery 2007, 11: 1498-1505. PMID: 17849166, DOI: 10.1007/s11605-007-0272-2.Peer-Reviewed Original ResearchConceptsBilateral colorectal liver metastasesColorectal liver metastasesPreoperative portal vein embolizationTwo-stage hepatectomyGroup IGroup IISystemic chemotherapyLiver metastasesSurvival rateDisease-free survival ratesBackgroundTwo-stage hepatectomyDay postoperative mortalityOne-stage hepatectomyPreoperative systemic chemotherapyGroup II patientsMedian hospital stayOutcomes of patientsPortal vein embolizationTreatment of patientsSecond-stage hepatectomyPostoperative mortalityAggressive surgeryBilateral diseaseHospital stayMajor hepatectomyEffect on patient outcome of residual DCIS in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy
Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo A, Symmans F, Meric-Bernstam F, Valero V, Hortobagyi G, Pusztai L. Effect on patient outcome of residual DCIS in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy. Journal Of Clinical Oncology 2007, 25: 530-530. DOI: 10.1200/jco.2007.25.18_suppl.530.Peer-Reviewed Original ResearchResidual invasive cancerInvasive cancerResidual DCISSurvival rateNeoadjuvant chemotherapyComplete eradicationDisease-free survival ratesLocal recurrence-free survivalRecurrence-free survival ratesUT MD Anderson Cancer CenterMD Anderson Cancer CenterResidual ductal carcinomaOutcomes of patientsPathologic complete responseRate of patientsInvasive breast cancerLocal recurrence rateOverall survival rateRecurrence-free survivalBreast cancer patientsAnderson Cancer CenterInclusion of casesPatients 78Residual invasivePreoperative chemotherapy
2005
Optimizing Adjuvant Endocrine Therapy in Postmenopausal Women With Early-Stage Breast Cancer: A Decision Analysis
Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. Optimizing Adjuvant Endocrine Therapy in Postmenopausal Women With Early-Stage Breast Cancer: A Decision Analysis. Journal Of Clinical Oncology 2005, 23: 5178-5187. PMID: 15998905, DOI: 10.1200/jco.2005.02.964.Peer-Reviewed Original ResearchConceptsDisease-free survivalDisease-free survival estimatesAromatase inhibitor monotherapyYears of tamoxifenAromatase inhibitorsSequential therapyBreast cancerInhibitor monotherapyPostmenopausal womenTreatment strategiesHormone receptor-positive breast cancerDisease-free survival ratesDistant disease-free survivalReceptor-positive breast cancerEarly-stage breast cancerSurvival estimatesAdjuvant endocrine therapyAromatase inhibitor therapyCross-over treatmentNode-positive patientsSequential adjuvant therapyPostmenopausal breast cancerRelative risk reductionRandomized clinical trialsSequential treatment strategyEpidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin‐based neoadjuvant chemotherapy
Buchholz TA, Tu X, Ang KK, Esteva FJ, Kuerer HM, Pusztai L, Cristofanilli M, Singletary SE, Hortobagyi GN, Sahin AA. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin‐based neoadjuvant chemotherapy. Cancer 2005, 104: 676-681. PMID: 15981280, DOI: 10.1002/cncr.21217.Peer-Reviewed Original ResearchMeSH KeywordsAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCyclophosphamideDisease-Free SurvivalDoxorubicinErbB ReceptorsFemaleFluorouracilHumansImmunohistochemistryNeoadjuvant TherapyPrognosisRandomized Controlled Trials as TopicSurvival AnalysisConceptsEpidermal growth factor receptorBreast carcinomaEGFR expressionAnthracycline chemotherapyLymph nodesEpidermal growth factor receptor expression correlatesSurvival ratePathologic complete response ratePretreatment tumor tissue samplesDisease-free survival ratesCox regression analysis modelComplete response rateEGFR-negative tumorsEGFR-positive diseasePositive lymph nodesAdvanced breast carcinomaMore lymph nodesOutcomes of patientsOverall survival rateProgesterone receptor statusEGFR-positive tumorsTumor tissue samplesKnowledge of outcomesGrowth factor receptorCyclophosphamide chemotherapy
2004
Iodine 125 Versus Palladium 103 Implants for Prostate Cancer
Peschel RE, Colberg JW, Chen Z, Nath R, Wilson LD. Iodine 125 Versus Palladium 103 Implants for Prostate Cancer. The Cancer Journal 2004, 10: 170-174. PMID: 15285926, DOI: 10.1097/00130404-200405000-00006.Peer-Reviewed Original ResearchConceptsExternal beam radiation therapyMinimum tumor doseDisease-free survival ratesComplication rateTumor doseProstate cancerRadiation therapyClinical outcomesPrognostic groupsBiochemical disease-free survival ratesSurvival rateBiochemical disease-free survivalDisease-free survivalHigh complication ratePoor prognostic groupProstate-specific antigenHormonal therapyT stageGleason scoreSingle institutionTransperineal implantationFavorable groupGrade 3Treatment groupsPatients
2001
Intrahepatic Cholangiocarcinoma: resectability, recurrence pattern, and outcomes1 1No competing interests declared.
Weber S, Jarnagin W, Klimstra D, DeMatteo R, Fong Y, Blumgart L. Intrahepatic Cholangiocarcinoma: resectability, recurrence pattern, and outcomes1 1No competing interests declared. Journal Of The American College Of Surgeons 2001, 193: 384-391. PMID: 11584966, DOI: 10.1016/s1072-7515(01)01016-x.Peer-Reviewed Original ResearchConceptsIntrahepatic cholangiocarcinomaVascular invasionHepatic tumorsMultiple tumorsFactors PredictiveActuarial 3-year survivalRare primary hepatic tumorDisease-free survival ratesFactors predictive of recurrencePredictive of poor survivalHistologically positive marginsOverall resection rateSite of recurrenceDisease-free survivalAdjuvant therapy strategiesPredictive of recurrencePrimary hepatic tumorsRecurrence patternsBile duct originPositive marginsComplete resectionCurative resectionMedian survivalTumor characteristicsProspective database
2000
Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous‐cell carcinoma of the cervix
Roberts K, Urdaneta N, Vera R, Vera A, Gutierrez E, Aguilar Y, Ott S, Medina I, Sempere P, Rockwell S, Sartorelli A, Fischer D, Fischer J. Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous‐cell carcinoma of the cervix. International Journal Of Cancer 2000, 90: 206-223. PMID: 10993961, DOI: 10.1002/1097-0215(20000820)90:4<206::aid-ijc4>3.0.co;2-o.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaDisease-free survivalMitomycin CSurvival rateRadical radiotherapyCervix cancerActuarial disease-free survival rateLocal recurrence-free survival rateActuarial disease-free survivalAdvanced squamous cell carcinomaOpen phase III trialDisease-free survival ratesRecurrence-free survival ratesDistant recurrence-free survivalAcute radiation reactionsIII-IVA patientsIntravenous mitomycin CMild hematologic toxicityNon-hematologic toxicitiesTreatment-related deathsActuarial survival rateAdvanced stage diseasePhase III trialsMitomycin C groupRecurrence-free survival
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply